Ισραήλ - Εβραϊκά - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

Ισραήλ - Εβραϊκά - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 2.5 mg - rivaroxaban

Ισραήλ - Εβραϊκά - Ministry of Health

glaxo smith kline (israel) ltd - ranitidine as hydrochloride - סירופ - ranitidine as hydrochloride 150 mg / 10 ml - ranitidine - ranitidine - h2 receptor antagonist. for treatment of duodenal ulcer and benign gastric ulcer, including that associated with nsaid agents. post-operative ulcer, oesophageal reflux disease and zollinger-ellison syndrome. prophylaxis of stress ulceration in seriously ill patients. before general anaesthesia in patients considered to be of risk acid aspiration (mendelson's syndrome).

Ισραήλ - Εβραϊκά - Ministry of Health

cts chemical industries ltd, israel - cyanocobalamin; pyridoxine (vit b6) hydrochloride; thiamine (vit b1) hydrochloride - טבליה - thiamine (vit b1) hydrochloride 100 mg; pyridoxine (vit b6) hydrochloride 250 mg; cyanocobalamin 0.25 mg - thiamine (vit b1) - thiamine (vit b1) - for the treatment of neurologic pain and metabolic disorders. vitamin b supplement.

Ισραήλ - Εβραϊκά - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - תמיסה להזרקה - glucose as monohydrate 10 % - glucose - glucose - as intravenous injection: dextrose 10 % injection is indicated as a source of water and calories. as parenteral nutrient: dextrose 10 % injection is indicated as a caloric component in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot should not be used. 2) gastrointestinal absorption of protein is impaired, or 3) metabolic requirements for protein are substantially increased, as extensive burns.

Ισραήλ - Εβραϊκά - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - תמיסה לאינפוזיה - glucose as monohydrate 20 g / 100 ml - glucose - glucose - dextrose injection is indicated as a caloric compnent in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirement sfor protein are substantially increases as extensive burns.

Ισραήλ - Εβραϊκά - Ministry of Health

teva medical ltd - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 50 % - glucose - glucose - dextrose 50 % injection is indicated as a caloric component in a parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot/should not be used 2) gastrointestinal absorption of protein is impaired or 3) metabolic requirements for protein are substantially increased , as with extensive burns.

Ισραήλ - Εβραϊκά - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - תמיסה לאינפוזיה - sodium lactate 0.32 %w/v; calcium chloride dihydrate 0.027 %w/v; potassium chloride 0.04 %w/v; sodium chloride 0.6 %w/v - calcium chloride - calcium chloride - source of water and electrolytes. regulation or maintenance of metabolic acidosis ( except lactic acidosis).

Ισραήλ - Εβραϊκά - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

Ισραήλ - Εβραϊκά - Ministry of Health

neopharm ltd - ranolazine 1000 mg - tablets extended release - ranolazine - ranexa is indicated for the treatment of chronic angina. ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers.